We use cookies to personalize your experience, track visits, and analyze traffic. Learn more.

👉🏼 Can’t watch 50+ talks in 3 days?

Get access to recordings, live Q&A panels, and our founding community

Upgrade to an All Access Pass to go deeper, integrate what they learn, and stay connected beyond the 3 days.

LEARN MORE

No recording access with your Free Summit Pass

Don’t miss an insight. Upgrade for on-demand access, live expert panels, and more👇🏼

Attend 9 live panels and engage with the experts

Join Q&A panels on critical topics. Ask your questions and gain key insights. Spots are limited for these live panels, upgrade today! Note: Only accessible with an All Access Pass.

Ethics and Safety in Psychedelic Therapy: Risks and Accountability

Psychedelics can heal, but they can also harm. Join Devon Christie, MD, Matthew Johnson, PhD, Sara Reed, MS, Bill Brennan, PhD, and Pedram Dara for a candid discussion on the ethical blind spots, safety risks, and accountability gaps emerging as the field expands. Discover what it will take to make psychedelic therapy safer, more transparent, and truly patient-centered.

🗓️ November 21 (Friday)
⏰ 8 AM PST | 11 AM EST | 17:00 CET
🎟️ Included in All Access Pass

Inside Psychedelic Trials: What Participants Want You to Know

Behind every clinical result is a human story. Leonie Schneider, Ian Roullier, Maryam Jabir, Kerrilee Barrett, and Pedram Dara share firsthand what it’s really like to participate in psychedelic clinical trials using DMT, psilocybin, MDMA, and other psychoactive substances for depression, anxiety, and PTSD. Learn what researchers miss, what participants need, and what it truly feels like to live the science.

🗓️ November 21 (Friday)
⏰ 10AM PST | 1PM EST | 19:00 CET
🎟️ Included in All Access Pass

Centering Lived Experience in Psychedelic Research and Training

What happens when lived experience becomes evidence? Join Michael Mithoefer, MD, Janis Phelps, PhD, Joost Breeksema, PhD, Rich Tyo, RP, and Pedram Dara as they explore how patient and participant voices can reshape the way we research, train, and deliver psychedelic therapy. This conversation is redefining the future of psychedelic education and care.

🗓️ November 21 (Friday)
⏰ 12PM PST | 3PM EST | 21:00 CET
🎟️ Included in All Access Pass

MDMA-assisted Therapy for PTSD: Lived Lessons and Blind Spots

The promise of MDMA therapy is real but so are its limits. Hear from Becca Kacanda, Brad Gagnon, Sehrish Sayani, Ron Bowman, and Pedram Dara who’ve undergone MDMA treatment through global clinical trials (including placebo and active arms) and Canada’s Special Access Program. This honest, in-depth conversation goes beyond the manuals to uncover breakthroughs, blind spots, and lessons learned from the inside out.

🗓️ November 22 (Saturday)
⏰ 8AM PST | 11AM EST | 17:00 CET
🎟️ Included in All Access Pass

Healing Trauma and Restoring Belonging Through Psychedelics

Trauma severs connection. Healing restores it. Join Rosalind Watts, PhD, Bessel van der Kolk, MD, Becca Kacanda, M.S., Shoshana Ward, RTC, and Pedram Dara to explore how psychedelic experiences may help trauma survivors rebuild safety, trust, and belonging and the challenges of sustaining that healing over time.

🗓️ November 22 (Saturday)
⏰ 10AM PST | 1PM EST | 19:00 CET
🎟️ Included in All Access Pass

Claim your limited-time offer

Unlock ongoing access to every session and 9 live panels with an All Access Pass, so you can absorb and apply every insight at your own pace.

Community
All Access Pass

For individuals seeking full summit access for knowledge, stories, and connection.

🎥 Full recordings of all sessions
💬 Live Q&A panels with experts
🌍 Community & discussion space
📚 Lived experience resources kit
🎧 Audio downloads + transcripts
📝 Summit implementation guide
🎁 Exclusive partner perks

$67 USD Save $80

Regular price: ~~$147~~

UPGRADE NOW

Professional
All Access Pass

For clinicians, practitioners, and researchers seeking exclusive professional benefits.

🎟 Everything in the Community Pass
🧑‍🏫 Workshop: lived experience in PAT
📘 Training early access: MDMA-AT
🤝 Professional networking sessions
🧭 Mentorship and supervision groups
📜 Certificate of summit participation
🚀 Priority invites to future initiatives

$97 USD Save $100

Regular price: ~~$197~~

UPGRADE NOW

To pay, use the same email you registered for the Free Summit Pass.

Psychedelics and Serious Illnesses: Fear, Meaning, and Mortality

A serious diagnosis can shake every part of life, identity, purpose, and hope. Join Anthony Back, MD, Emma Hapke, MD, Anne Hamilton, and Florence Moureaux for an intimate discussion on how psychedelics are being used to help people living with cancer and other serious illnesses navigate fear, reconnect with meaning, and find emotional and spiritual healing in the midst of existential distress.

🗓️ November 22 (Saturday)
⏰ 12PM PST | 3PM EST | 21:00 CET
🎟️ Included in All Access Pass

Beyond Treatment: Integration, Aftercare, and Lasting Effects

Healing doesn’t end with the session, it begins there. Join Marcela Ot’alora, MFA, Bruce Poulter, RN, MPH, Kim Fluxgold, Julia King Olivier, MD, and Corine de Boer, MD, PhD, to explore the long road of integration and recovery. From unexpected symptoms to the ongoing need for support, this panel exposes where our current systems fall short and how to do better.

🗓️ November 23 (Sunday)
⏰ 8AM PST | 11AM EST | 17:00 CET
🎟️ Included in All Access Pass

What Really Heals in Psychedelic Therapy: Drug, Placebo, or Care?

Is healing driven by the medicine, the meaning, or the mystery? Join Craig Heacock, MD, Berra Yazar-Klosinski, PhD, Elizabeth Lamphere, and Kathy Neustadt for a fascinating look at the true mechanisms of transformation. Explore how chemistry, connection, and care intertwine to create lasting change.

🗓️ November 23 (Sunday)
⏰ 10AM PST | 1PM EST | 19:00 CET
🎟️ Included in All Access Pass

Lived Experience as Expertise: Redefining Psychedelic Healthcare

What if those who’ve been through treatment helped design and deliver it? Join Tehseen Noorani, PhD, Jon Nelson, Katie Bourque, Roy Dings, and Pedram Dara as they introduce a new model of lived-experience-led education and certification. Meet the voices transforming psychedelic and mental healthcare from the inside out.

🗓️ November 23 (Sunday)
⏰ 12PM PST | 3PM EST | 21:00 CET
🎟️ Included in All Access Pass

Unlock the full summit experience today!

The All Access Pass was carefully prepared for you to get the most value out of the summit and get maximum results, with minimal time commitment. And if you upgrade today, you'll save as an early supporter.

Community
All Access Pass

For individuals seeking full summit access for knowledge, stories, and connection.

$67 USD Save $80

Regular price: ~~$147~~

UPGRADE NOW

Professional
All Access Pass

For clinicians, practitioners, and researchers seeking exclusive professional benefits.

$97 USD Save $100

Regular price: ~~$197~~

UPGRADE NOW

To pay, use the same email you registered for the Free Summit Pass.

Need a scholarship?

We believe cost shouldn’t be a barrier to participation. A limited number of partial and full scholarships are available for attendees from lower-income regions, students, and those in financial need. Apply below to request one.

APPLY NOW

Get $700+ worth of value with an All Access Pass

	Free Summit Pass	All Access Pass
Summit access (only valid on Nov 21-23)	✅	✅
On-demand access to all recordings	❌	✅
Live Q&A panels with summit experts	❌	✅
Networking sessions & breakout rooms	❌	✅
Community platform early access	❌	✅
Audio edition of the entire summit	❌	✅
Transcripts & summaries of all sessions	❌	✅
Implementation guide document	❌	✅
Curated resource library & partner perks	❌	✅
Workshop & training on lived experience	❌	✅ Professional Pass

Here's everything you get with the All Access Pass

Clinical and scientific speakers

Join leading researchers and clinicians in psychedelic science as they share insights on integrating lived experience to improve clinical trials, therapist training, and treatment outcomes.

NOTE: Speakers featured for expertise only; views/actions aren’t endorsed. Learn more ->

Bessel van der Kolk, MD

Psychiatrist, author of The Body Keeps the Score, and principal investigator for MDMA-assisted therapy for PTSD trials (U.S.)

Rosalind Watts, PhD

Clinical psychologist, ACER Integration founder, and former psilocybin clinical lead at Imperial College London (UK)

Michael Mithoefer, MD

Psychiatrist, clinical researcher, and medical monitor for MDMA-assisted psychotherapy for PTSD clinical trials (U.S.)

Marcela Ot’alora, MFA

Therapist, lead trainer, supervisor, and principal investigator for MDMA-assisted therapy for PTSD clinical trials (U.S.)

Bruce Poulter, RN, MPH

Therapist, lead trainer, supervisor, and sub-investigator for MDMA-assisted therapy for PTSD clinical trials (U.S.)

Corine de Boer, MD, PhD

Pediatrician, researcher, former Chief Medical Officer at Lykos/MAPS PBC, and founder & CEO at Tulip Medical Consulting (U.S.)

Matthew Johnson, PhD

Psychedelic researcher, experimental psychologist, senior investigator, and professor at Johns Hopkins School of Medicine (U.S.)

Monnica Williams, PhD

Clinical psychologist, researcher, and professor in the School of Psychology at University of Ottawa (Canada)

Jonathan Dickinson

Psychologist, renowned Ibogaine expert, published researcher, and CEO & co-founder at Ambio Life Sciences (Mexico/Canada)

Janis Phelps, PhD

Clinical psychologist, founder and director of the CIIS Center for Psychedelic Therapies and Research (U.S.)

Sandeep Nayak, MD

Psychiatrist, psilocybin clinical researcher, and associate professor at Johns Hopkins University (U.S.)

Sara Reed, MS

Marriage and family therapist, lead psychedelic clinical trial therapist at Imperial College London (UK)

Paul Liknaitzky, PhD

Psychologist, clinical researcher and head of Clinical Psychedelic Lab at Monash University (Australia)

Devon Christie, MD

Family physician and therapeutic counsellor, investigator for Phase 3 MDMA-assisted therapy for PTSD trials (Canada)

Manesh Girn, PhD

Neuroscientist, researcher at UCSF working with Robin Carhart-Harris, PhD on the impact of psychedelics on mental health (U.S.)

Emma Hapke, MD

Psychiatrist and clinical researcher for MDMA therapy for PTSD and psilocybin for advanced cancer trials (Canada)

Chris Stauffer, MD

Psychiatrist and addiction medicine specialist, group MDMA therapy investigator for veterans with PTSD (U.S.)

Simon Ruffell, MD, PhD

Psychiatrist, research psychologist with PhD in ayahuasca and mental health, lecturer at the University of Exeter (UK)

Joost Breeksema, PhD

Qualitative researcher in psychedelic trials and executive director of the OPEN Foundation (Netherlands)

Pamela Kryskow, MD

Physician, board member of the Psychedelic Association of Canada and medical lead at the Roots to Thrive (Canada)

Houman Farzin, MD

Palliative care physician and psychedelic therapist specializing in psilocybin therapy for terminal illness (Canada)

Julia King Olivier, MD

Psychiatrist, psychedelic therapist, and founder of the Compassionate Care Center in Geneva (Switzerland)

Simon Amar, MD

Psychiatrist, investigator for MDMA therapy for PTSD trials (Canada) and psilocybin for anxiety trials (Australia)

Shoshana Ward, RTC

Therapist specializing in medicine assisted therapy, clinic director & co-founder at Centre for Medicine Assisted Therapy (Canada)

Bill Brennan, PhD

Psychologist, clinical researcher, psychedelic educator, author, and supervisor to therapists on clinical trials (U.S.)

Chloé Pronovost-Morgan, MD, MSc

Psychiatry resident and lead author on Delphi study for reporting of setting in psychedelic trials (Canada)

Will Barone, Psy.D

Clinical psychologist and qualitative researcher in MDMA therapy for terminal illness and studies with psilocybin & ketamine (U.S.)

Lived experience speakers

Hear from former patients and trial participants in treatments with MDMA, Psilocybin, LSD, Ketamine, 5-MeO-DMT, Ibogaine and other psychoactive substances. Their stories offer powerful insights to improve research design, therapist training, and future treatment outcomes.

Why aren’t all lived experiences represented? Learn more ->

Brad Gagnon

MDMA-assisted therapy for PTSD, special access program patient (Canada, 2024)

Becca Kacanda, M.S.

MDMA-assisted psychotherapy for PTSD, Phase 3 trial participant (active arm, U.S., 2021)

Mark Keller

Ibogaine & 5-MeO-DMT for PTSD, anxiety, & addiction, clinical treatment patient (Mexico/U.S. 2022-23)

Juliana Mulligan, LMSW

Ibogaine for opioid dependency, clinical treatment patient & therapist (U.S. 2011)

Ian Roullier

Psilocybin for depression pilot study and phase 2 clinical trials participant (UK, 2015 and 2019)

Maya Albert

Psilocybin-assisted therapy for anorexia nervosa, Phase 1 trial participant (open-label, U.S., 2021)

Daniel Friedrich

U.S. veteran, peer support and study facilitator for MDMA and psilocybin studies (U.S.)

Kim Fluxgold

Psilocybin for treatment-resistant depression, clinical trial participant (open-label, Canada, 2022)

Jana Sladkova, PhD

Group ketamine therapy & SPRAVATO® (esketamine) for depression, treatment patient (U.S., 2025)

Leonie Schneider

Psilocybin and DMT for depression clinical trials participant (UK, 2019 and 2022)

Ian Cook

Ketamine therapy for bipolar I, depression, and anxiety, clinical treatment patient (U.S., 2022)

Maryam Jabir

Psilocybin for treatment-resistant depression, Phase 2 clinical trial participant (UK, 2021)

Andrea Siclari

LSD-assisted therapy for life-threatening illness, compassionate use patient (Switzerland, 2020)

Lauren Macdonald, MD

Legal psilocybin retreat for terminal cancer participant, psychiatrist, trial doctor & therapist (UK, 2018)

Cedric Codron

SPRAVATO® (esketamine) for depression, clinical treatment patient (Belgium, 2022)

Florence Moureaux

Psilocybin-assisted therapy for terminal cancer, special access program patient (Canada, 2021)

Sehrish Sayani

MDMA-assisted therapy for PTSD, Phase 3 trial participant (placebo then crossover, U.S., 2023)

Janina Kowalski, MD

Ketamine, MDMA, LSD, and Psilocybin for experiential therapist training study (Switzerland, 2025)

Sarko Gergerian

MDMA-assisted therapy in experiential training for a police officer-therapist (U.S., 2018)

Kathy Neustadt

MDMA-assisted therapy for PTSD, Phase 3 trial participant (placebo only, U.S., 2021)

Ron Bowman

MDMA-assisted psychotherapy for PTSD, Phase 3 trial participant (active arm, U.S., 2020)

Leonie McCoy

Psilocybin-assisted therapy for generalized anxiety disorder, clinical trial participant (Australia, 2022)

Kerrilee Barrett

Psychoactive substance for PTSD Phase 2 clinical trial participant (double blinded then open label, UK, 2024)

Daryna Skybina, MPS

Psilocybin-assisted therapy for advanced cancer trial participant, registered therapist (Canada, 2025)

Jules Heighton

MDMA-assisted massed exposure therapy for PTSD, Phase 2 trial participant (open-label, U.S., 2025)

Heather Joy

Psilocybin for treatment-resistant depression, clinical trial participant (open-label, Canada, 2022)

Frank Sers

MDMA and LSD assisted therapies for depression, compassionate use patient (Switzerland, 2022)

Upgrade to an All Access Pass and receive:

🎥 All session recordings: Rewatch all expert interviews anytime, at your own pace.

💬 Live panel discussions: Connect directly with experts and ask your questions live.

💻 Networking sessions: Join breakout rooms and connect with the summit community.

🌍 Community platform access: Be the first to join our upcoming membership space.

🎧 Audio downloads: Listen anytime, anywhere—perfect for learning on the go.

📝 Transcripts & summaries: Get key takeaways without rewatching every session.

📖 Implementation guide: A step-by-step document on applying key summit insights.

📚 Curated resource library: Books, media, and research papers on lived experience.

🎁 Exclusive partner perks: Special offers and discounts from our trusted partners.

⭐ Bonus workshop & training: Professional All Access Pass holders can join a dedicated workshop and be among the first to access our upcoming training: Lived Experience in MDMA Therapy for PTSD.

Unlock the full summit experience today!

Get the lowest price as an early supporter before our operational costs rise with more attendees. With no sponsorship funding, all expenses for support, platform, and fees come out of pocket. That’s why the best deal is always right now. Upgrade today!

Community
All Access Pass

For individuals seeking full summit access for knowledge, stories, and connection.

$67 USD Save $80

Regular price: ~~$147~~

UPGRADE NOW

Professional
All Access Pass

For clinicians, practitioners, and researchers seeking exclusive professional benefits.

$97 USD Save $100

Regular price: ~~$197~~

UPGRADE NOW

To pay, use the same email you registered for the Free Summit Pass.

Support a nonprofit mission

Upgrading to All Access Pass helps launch the

Psychedelic Lived Experiences Association (PLEA)

a new nonprofit advancing lived experience in

psychedelic research, treatment, and policy.

Need a scholarship?

APPLY NOW

Frequently Asked Questions

When does the limited-time deal end?

The Community All Access pass is just $67 before it goes up to $147 (after Nov 21). The Professional All Access pass is just $97 before it goes up to $197 (after Nov 21). Prices increase as the summit approaches and our operational costs rise with more attendees. We suggest locking in the lowest price before rates go up! Price increases happen without notice. With no sponsorship funding, we personally cover all expenses. The best deal is always now!

What's the difference between Community and Professional pass?

The Community All Access Pass is for general attendees seeking full summit access at the lowest rate ever. It provides full access to all recordings, live panels, community, resources, and other exclusive content. However, the Professional all Access Pass is designed for therapists, physicians, researchers, coaches, and practitioners. You'll get everything from the Community Pass plus access to a hands-on group workshop and early access to our new training (lived experience in MDMA therapy for PTSD). Your purchase directly supports our mission, funds our peer support groups, and helps subsidize scholarships for others. Thank you!

Are there group discounts available?

Yes! Joining together is more fun. To inquire about group discounts, send us an email. >>> contact@psychedeliclivedexperiences.com

How will I receive what's included in the All Access Pass?

After you place your order, you’ll receive a confirmation email with all the details. All materials and resources will become available starting November 21, 2025, the first day of the summit. Some items—such as transcripts, the implementation guide, and live panel replays—may be added after the summit as final processing is completed. You’ll receive everything directly by email for easy, 1-year access.

How can I watch or listen to the session recordings?

You can stream session recordings in your web browser (Chrome, Safari, Edge, etc.) on your computer, phone, or tablet—or listen on the go. When you upgrade to an All Access Pass, you’ll get full access to all materials as they’re released—starting November 21, 2025 and continuing after the summit as new content becomes available.

Can I buy the All Access Pass as a gift? How do I contact you?

Of course! You can make the purchase with your own email address and then contact us to transfer it to the person you want to gift it to. >>> contact@psychedeliclivedexperiences.com